The study intends to evaluate the tolerability and efficacy of BC 007 in Long Covid patients. Credit: Mai.Chayakorn/Shutterstock.com.

Berlin Cures has initiated a Phase II clinical trial of its lead drug candidate BC 007 in the indication Long Covid.

BC 007’s potential is based on the data generated in the lab using sera from patients with Long Covid. Four cases have been studied to date.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The first patients in the study were admitted to Havelhöhe and Münster University hospitals in Germany.

The study intends to evaluate the tolerability and efficacy of BC 007 in Long Covid patients and obtain meaningful and robust results.

Positive data from this study will be used to initiate a larger Phase III study.

The first results of the Phase II clinical trial are anticipated early next year.

Clinical development of the drug will be supported by Dr Axel Mescheder, Berlin Cures’ new chief medical officer (CMO).

Berlin Cures CEO Oliver von Stein said: “As CMO, he will be a driving force behind Berlin Cures’ efforts to bring relief and a cure to patients suffering from functional autoantibodies (fAAB)-associated diseases.

“Together, we will work towards transforming our platform technology into a therapeutic solution for millions of patients.”

BC 007 molecule effectively neutralises fAAB. Its effectiveness has been observed in a Phase I study in fAAB-positive healthy volunteers and Phase IIa trial in patients with heart failure.

Mescheder said: “Berlin Cures’ platform technology holds the potential to effectively treat multiple autoimmune diseases by targeting fAABs as their root cause.

“With the inclusion of patients in the clinical Phase II trial in Long Covid, we are jointly taking the next important step to advance the development of BC 007.”